Wilmington, DE – Incyte has announced the appointment of Pablo Cagnoni as President and Global Head of Research and Development. About Incyte: Incyte is a global biopharmaceutical company founded in 2002 in Wilmington, Delaware, that specializes in discovering and developing innovative treatments across hematology, oncology, and inflammation and autoimmunity. The company has grown from its origins as a small group of scientists, chemists, and biologists into a global organization with more than 2,800 employees operating across North America, Europe, and Asia, including approximately 1,000 dedicated to research and clinical development. Incyte has built a robust and diversified portfolio consisting of 9 approved products with ongoing clinical trials spanning dozens of disease areas, demonstrating its commitment to addressing unmet medical needs for patients worldwide. The company has been recognized for its commitment to innovation and workplace excellence, having been named to the Science Magazine top employers list for 8 consecutive years, and operates with a mission centered on integrity, ethical conduct, and patient-centered innovation to improve the lives of those it serves.

For more information on Incyte please visit: https://incyte.com/

Incyte
1801 Augustine Cut-Off
Wilmington, DE 19803
Phone: 855-463-3463
LinkedIn Page: https://www.linkedin.com/company/incyte/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved